These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
367 related articles for article (PubMed ID: 27908558)
1. Time-Varying Risk for Breast Cancer Following Initiation of Glucose-Lowering Therapy in Women with Type 2 Diabetes: Exploring Detection Bias. Bowker SL; Lin M; Eurich DT; Johnson JA Can J Diabetes; 2017 Apr; 41(2):204-210. PubMed ID: 27908558 [TBL] [Abstract][Full Text] [Related]
2. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Bowker SL; Majumdar SR; Veugelers P; Johnson JA Diabetes Care; 2006 Feb; 29(2):254-8. PubMed ID: 16443869 [TBL] [Abstract][Full Text] [Related]
3. Intensification with dipeptidyl peptidase-4 inhibitor, insulin, or thiazolidinediones and risks of all-cause mortality, cardiovascular diseases, and severe hypoglycemia in patients on metformin-sulfonylurea dual therapy: A retrospective cohort study. Wong CKH; Man KKC; Shi M; Chan EW; Ho CW; Tse ETY; Wong ICK; Lam CLK PLoS Med; 2019 Dec; 16(12):e1002999. PubMed ID: 31877127 [TBL] [Abstract][Full Text] [Related]
4. Comparative safety of diabetes medications and risk of incident invasive breast cancer: a population-based cohort study. Calip GS; Yu O; Elmore JG; Boudreau DM Cancer Causes Control; 2016 May; 27(5):709-20. PubMed ID: 27053250 [TBL] [Abstract][Full Text] [Related]
5. Initial metformin or sulphonylurea exposure and cancer occurrence among patients with type 2 diabetes mellitus. Qiu H; Rhoads GG; Berlin JA; Marcella SW; Demissie K Diabetes Obes Metab; 2013 Apr; 15(4):349-57. PubMed ID: 23137378 [TBL] [Abstract][Full Text] [Related]
6. Medical therapy for diabetes is associated with increased use of lower endoscopy. Lewis JD; Capra AM; Achacoso NS; Ferrara A; Levin TR; Quesenberry CP; Habel LA Pharmacoepidemiol Drug Saf; 2007 Nov; 16(11):1195-202. PubMed ID: 17603822 [TBL] [Abstract][Full Text] [Related]
7. Metformin reduces ovarian cancer risk in Taiwanese women with type 2 diabetes mellitus. Tseng CH Diabetes Metab Res Rev; 2015 Sep; 31(6):619-26. PubMed ID: 25820555 [TBL] [Abstract][Full Text] [Related]
8. Are sulfonylurea and insulin therapies associated with a larger risk of cancer than metformin therapy? A retrospective database analysis. Kowall B; Rathmann W; Kostev K Diabetes Care; 2015 Jan; 38(1):59-65. PubMed ID: 25336750 [TBL] [Abstract][Full Text] [Related]
9. Important differences in the durability of glycaemic response among second-line treatment options when added to metformin in type 2 diabetes: a retrospective cohort study. Mamza J; Mehta R; Donnelly R; Idris I Ann Med; 2016; 48(4):224-34. PubMed ID: 26982210 [TBL] [Abstract][Full Text] [Related]
11. Long-term comparative safety analysis of the risks associated with adding or switching to a sulfonylurea as second-line Type 2 diabetes mellitus treatment in a US veteran population. Powell WR; Christiansen CL; Miller DR Diabet Med; 2019 Nov; 36(11):1384-1390. PubMed ID: 30343492 [TBL] [Abstract][Full Text] [Related]
12. Evaluation of adverse events of oral antihyperglycemic monotherapy experienced by a geriatric population in a real-world setting: a retrospective cohort analysis. Asche CV; McAdam-Marx C; Shane-McWhorter L; Sheng X; Plauschinat CA Drugs Aging; 2008; 25(7):611-22. PubMed ID: 18582148 [TBL] [Abstract][Full Text] [Related]
13. The Risk of TB in Patients With Type 2 Diabetes Initiating Metformin vs Sulfonylurea Treatment. Pan SW; Yen YF; Kou YR; Chuang PH; Su VY; Feng JY; Chan YJ; Su WJ Chest; 2018 Jun; 153(6):1347-1357. PubMed ID: 29253553 [TBL] [Abstract][Full Text] [Related]
14. Risk of overall mortality and cardiovascular events in patients with type 2 diabetes on dual drug therapy including metformin: A large database study from the Cleveland Clinic. Kannan S; Pantalone KM; Matsuda S; Wells BJ; Karafa M; Zimmerman RS J Diabetes; 2016 Mar; 8(2):279-85. PubMed ID: 25929426 [TBL] [Abstract][Full Text] [Related]
15. The risk of coronary heart disease in type 2 diabetic patients exposed to thiazolidinediones compared to metformin and sulfonylurea therapy. Johannes CB; Koro CE; Quinn SG; Cutone JA; Seeger JD Pharmacoepidemiol Drug Saf; 2007 May; 16(5):504-12. PubMed ID: 17245800 [TBL] [Abstract][Full Text] [Related]
16. Glucose-lowering agents and cancer mortality rates in type 2 diabetes: assessing effects of time-varying exposure. Bowker SL; Yasui Y; Veugelers P; Johnson JA Diabetologia; 2010 Aug; 53(8):1631-7. PubMed ID: 20407744 [TBL] [Abstract][Full Text] [Related]
17. Progression to insulin for patients with diabetes mellitus using the Texas Medicaid database. Rascati KL; Richards KM; Lopez D; Cheng LI; Wilson JP Clin Ther; 2011 Dec; 33(12):2016-20. PubMed ID: 22101160 [TBL] [Abstract][Full Text] [Related]
18. Gender-specific effects of oral hypoglycaemic agents on cancer risk in type 2 diabetes mellitus. Sun GE; Wells BJ; Yip K; Zimmerman R; Raghavan D; Kattan MW; Kashyap SR Diabetes Obes Metab; 2014 Mar; 16(3):276-83. PubMed ID: 24199848 [TBL] [Abstract][Full Text] [Related]
19. Thiazolidinediones and cardiovascular events in patients with type 2 diabetes mellitus: a retrospective cohort study of over 473,000 patients using the National Health Insurance database in Taiwan. Hsiao FY; Huang WF; Wen YW; Chen PF; Kuo KN; Tsai YW Drug Saf; 2009; 32(8):675-90. PubMed ID: 19591532 [TBL] [Abstract][Full Text] [Related]
20. Combination therapy with sulfonylureas and metformin and the prevention of death in type 2 diabetes: a nested case-control study. Azoulay L; Schneider-Lindner V; Dell'aniello S; Schiffrin A; Suissa S Pharmacoepidemiol Drug Saf; 2010 Apr; 19(4):335-42. PubMed ID: 20052677 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]